Affinium Pharmaceuticals announces completion of recruitment for Phase 2 clinical trial of AFN-1252

Affinium Pharmaceuticals announced that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI"). This Phase 2 trial is the first human efficacy study conducted with a new class of an tibiotics designed to specifically inhibit staphylococcal fatty acid biosynthesis via a new drug target, the fatty acid synthase II (FASII) system. Results expected in late 2012 will represent a significant proof-of-concept milestone for this unique, Staphylococcus-specific antibiotic, AFN-1252.

The objectives of the study are to confirm efficac y, safety and tolerability of 200 mg of oral AFN-1252 dosed twice daily for 5-14 days in patients with serious, suspected staphylococcal skin infections recruited in the outpatient or emergency room settings. The trial evaluates both the traditional endpoints at end of treatment a nd early endpoints currently recommended by the FDA.

"We are delighted with the ease and rate of patient recruitment in our study," said Dr. Barry Hafkin, Chief Medical Officer at Affinium. Dr. Hafkin noted that investigators had the option of adding a second antibiotic to cover any other pot ential pathogen or admitting the patient into hospital; yet, the majority of the patients we re treated with AFN-1252 as monotherapy in the outpatient setting. "We believe this study demonstrates investigators' confidence in identifying staphylococcal skin infection and using AFN-1252 in the treatm ent of serious staphylococcal skin infections. The exquisite potency of AFN-1252 agains t all strains of Staphylococcus including MRSA and VISA through a unique new m echanism of action, and the excellent safety profile demonstrated in multiple oral Phase 1 studies were attributes that excited our clinical investigators," Dr. Hafkin noted.

According to Leisa Dennehy, Commercial & Corporate Development Advisor at Affinium, "Practicing physicians and key opi nion leaders consistently remark that a specific-spectrum agent has unique and important benefits that no other antibiotic has ever been able to offer." Robert Daum, M.D., Director of the Univers ity of Chicago MRSA Research Center and Professor of Pediatrics, Microbiology and Molecular Medicine at the University of Chicago, Illinois, commented: "A staphylococcal specific antibiotic should have no off-target effect on gut flora and put no resistance selection pressure on other bacterial spec ies, which may greatly reduce the probability of antibiotic associated adverse events such as C. difficile disease, diarrhea or candidiasis. The incredible potency against all strains of Staphylococcus combined with an excellent safety profile demonstrated in multip le oral Phase 1 makes AFN-1252 an exciting new product for treatment of staphylococcal infections."

About Staphylococcal Infections
Each year in the US, more people die from staphylococcal infections that from HIV. Skin infections alone account for more ten million patient visits in the US. Staphylococcus is the mostly commonly identified bacterium in skin infections and is a poten tial pathogen in almost every infection type, making staphylococci the most common bacterial pathogen in a large and diverse patient population.

About AFN-1252
AFN-1252 is the lead clinical-stage agent in a new class of antibiotics base d on FabI inhibition. AFN-1252 is a well tolerated and highly potent agent that is ac tive against all strains of Staphylococcus, including all known resistant strains such as methicillin-resistant S.aureus (MRSA) and vancomycin-intermediate S.aureus (VISA). Because AFN-1252 is specifically designed to be active against only Staphylococcus sp., it may provide the unique safety benefit of no off-target side effects, such as antibiotic-induced diarrhea or resistance pressure on other bacteria. AFN-1252 has potential to be used eith er as monotherapy for confirmed staphylococcal infections or in combination when Staphylococcus is suspected in a variety of infections. The oral formulation is finishing Ph ase 2a, and the IV formulation is completing pre-clinical studies in 2012.

About Affinium Pharmaceuticals
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium fatty acid synthesis ("FASII") antibacterial program constitutes a new antibiotic franchise with the potential for multiple patented products targeting the FASII pathway in various bacteria.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...